Biotech Values

[jbog]

I'm not sure I'd give Dan a B at this point. What I see as the current determent is that Revance is going to go through the complete funding and still lack approvals.

We'll be back in the same position one year from now but hopefully on the footsteps of approval.

The slowness of submitting the data, while the checks continue to be written is the cause of the diminished stock excitement.